Ethylene

Ethylene

SCHEMBL3595933

C=C.O=C1CCc2ncc([N+](=O)[O-])cc2C1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
TYMS P04818 1/20 0.34
IDO1 P14902 1/20 0.33
TDP2 O95551 1/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
MAPT P10636 4/20 0.33
KAT2B Q92831 2/20 0.33
LMNA P02545 2/20 0.32
RAB9A P51151 1/20 0.32
TLR9 Q9NR96 1/20 0.32
ADRA2A P08913 1/20 0.32
PNMT P11086 1/20 0.32
CCNA2 P20248 1/20 0.32
CDK2 P24941 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3577632 0.97 ALDH1A1 (0.38) ALDH1A1MAPK1HTTTYMSIDO1
SCHEMBL13341660 0.76 ALDH1A1 (0.43) ALDH1A1MAPK1HTTIDO1MEN1
SCHEMBL5582661 0.76 CCNA2 (0.46) ALDH1A1MAPK1HTTIDO1MEN1
SCHEMBL6210831 0.74 ALDH1A1 (0.45) ALDH1A1MAPK1HTTIDO1MEN1
SCHEMBL5457968 0.72 ALDH1A1 (0.38) ALDH1A1MAPK1HTTIDO1MEN1
SCHEMBL30831356 0.71 PNMT (0.56) ALDH1A1MAPK1HTTIDO1MAPT
SCHEMBL3822440 0.71 PNMT (0.56) ALDH1A1MAPK1HTTIDO1MAPT
SCHEMBL6776635 0.71 RXFP1 (0.40) ALDH1A1MAPK1HTTIDO1MEN1
SCHEMBL6772199 0.71 ALDH1A1 (0.37) ALDH1A1MAPK1HTTTYMSIDO1
SCHEMBL5463026 0.70 ALDH1A1 (0.36) ALDH1A1MAPK1HTTIDO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same RENOVIS, INC. (US) 2010-01-07 US disclosed
EP-1954132-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2008-08-13 EP disclosed
WO-2007100758-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004222-A1 Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same TRPV1, TRPA1, TRPV2 ALDH1A1 1265/4885MAPK1 1154/4885HTT 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.